Key Takeaways
- A brutal reset, framed as a one-off: Profit collapsed from ₹445 crores to ₹166 crores as the "triple whammy" of Ibuprofen price decline, volume drop, and trapped input costs hit simultaneously. Management calls the prior peak unsustainable and urges investors to look through to a steadier 18–20% EBITDA future.
- Ibuprofen is the problem, and it is not over: Volumes fell ~1,000 tons and pricing dropped Rs.80–100/kg as customers worked through pandemic-era overstocking. Management believes pricing has bottomed, but a real recovery waits on destocking ending, likely in H2 FY23.
- The chemical business swung to a loss: A raw-material-to-product-price flip turned ethyl acetate margins negative in Q4. Management insists the long-term 6–8% EBITDA average holds and Q1 FY23 will already be better.
- A diversification story is being built, not yet delivered: Non-Ibuprofen pharma is now 35% of the segment, Paracetamol revenue just began, and new chemical products are a year away. The promise is real but the numbers are still small.
- What to watch next quarter: Whether Ibuprofen volumes actually begin to tick up from Q2 as guided, whether chemical margins return to positive territory, and any concrete naming of the new chemical products.
The Ibuprofen Reset
- Volume destruction: FY22 volumes declined by almost 1,000 tons versus FY21, to approximately 8,000–8,300 tons, because overstocking by customers from the previous year has still not been fully absorbed.
- Pricing collapse: Weighted average price fell from $12–$13/kg in FY21 to $11–$11.5/kg in FY22, a drop of Rs.80–100 per kg, driven by a demand-supply imbalance and customer destocking.
- The triple hit to pharma profits: Segment profit dropped from Rs.460 crores to Rs.160 crores because of a price decline of ~Rs.50/kg on ~9,000 tons, a volume decline of ~1,000 tons removing ~Rs.85 crores from the top line, and lower asset utilization increasing average manufacturing cost, all compounded by higher input and energy costs.
- Input cost pass-through failed: Only a "small fraction" of increased input costs could be passed on to customers, which management identifies as the primary reason for the profit decline.
- Pricing floor call: Management believes current pricing is the lowest level seen in the last couple of years and expects prices to increase once the overstocking issue resolves, driven by input cost pressure with a phase lag of 1–2 quarters.
- Competitive supply tightening: Several competing suppliers have lowered capacities or are not backward integrated, putting more pressure on their businesses; management expects they will shift focus to more profitable products, tightening supply and pushing prices up.
- Early positive signals exist but are unconfirmed: Some overseas long-term contract customers are showing "a sense in the positive direction"; a clearer picture is expected by Q2 FY23 on whether this is a strategic shift or an aberration.
- Q1 FY23 run-rate: Ibuprofen volumes in Q1 FY23 are expected to be similar to Q4 FY22, with a volume uptick expected from Q2 FY23 onwards.
Chaturvedi: "most certainly this is the lowest level of Ibuprofen crisis that we have seen in the last couple of years."
Chemical Business: A Margin Flip and a Promise
- Q4 loss mechanics: The loss was a function of buying acetic acid and, by the time it was used, the price of ethyl acetate had come down, creating a flip situation where raw material price was much higher than product price. In previous quarters, the opposite occurred, leading to EBITDA numbers well beyond 8%.
- Long-term average intact: On an annual basis, the company expects to continue making 6% to 8% EBITDA on the chemicals business; management states there is no structural factor to be concerned about for long-term average EBITDA margins.
- Q1 FY23 recovery expected: Q1 will certainly be better than Q4 because acetic acid was bought when prices went down; management says it will certainly be in positive single digits but is preliminary on whether it returns to the 6–8% range immediately.
- Single-product concentration risk: The business is primarily based on one product, ethyl acetate, whose key raw material, acetic acid, relies entirely on imports, challenging profitability management when dependent on a single product with imported raw material cost.
- No silver bullet for sourcing: Management describes its approach as carrying higher inventories, maintaining strategic key account relationships, and using market intelligence to make "educated predictions and guesses," but confirmed there is no specific hedging mechanism or formula-based pricing.
- Export push beginning: Ethyl acetate export price realization is somewhat better than domestic, but it will take "a few quarters to achieve the kind of potential we want."
Chaturvedi: "I want to look at this as an average of what we do rather than a quarter-by-quarter. So, the message I want to leave you with... is the business is not under threat."
Diversification: The Build Phase
Non-Ibuprofen Pharma
- Current scale: Non-Ibuprofen pharma now contributes about 20% to quarterly revenue and about 35% of pharma segment revenue.
- Products driving growth: Metformin, Clopidogrel, Pantoprazole, and Levetiracetam are the named contributors.
- Margin trajectory: Current single-digit EBITDA margins are primarily because asset utilization is still low despite capacities being set up; management expects these to "certainly go into double digits this year."
- Asset utilization ramp: Expected to improve from 50–60% to 75–80% in the next 12 to 18 months.
- Metformin regulated markets: Regulatory papers have been filed and are in the approval process, expected to take "a few more quarters" to achieve approvals and enter regulated export markets.
- Metformin pricing normalization: Earlier in the year, India prices were higher than export prices, an unusual situation; this has now reversed to normal where India prices are significantly lower than export prices.
Paracetamol
- Operational now: The plant is running at 1,800 tons per year capacity and revenue booking started in Q4 FY22.
- Doubling capacity: Plan to double capacity to 3,600 tons per year by the end of CY22.
New Chemical Products
- Timeline: CAPEX is being put on the ground now and will take about one year; commercial activity is expected by the end of this financial year or early next year, with numbers starting to be seen in FY24.
- Customer base: Products will go into a similar customer base to what the company has today, leveraging existing commercial infrastructure.
- Margin ambition: New products launched will have EBITDA numbers "certainly higher than 6% to 8%."
- Growth target: Management is targeting double-digit growth of 10% to 20% every year in a sustained way for the chemicals division, between debottlenecking of the ethyl acetate plant and new product expansions.
Chaturvedi: "There is a thumb rule to remember is if you want to have a significant growth in a business that business must grow by at least double digits, 10% to 20%. So, that is a kind of figure that we are targeting initially, and the idea is to add that kind of growth in a sustained way."
Margin Architecture and the Path Back
- FY22 delivered 13% EBITDA: The full-year margin came in at 13% despite volatility from volume and raw material pricing headwinds.
- FY23 target of 15%+: Management intends to take overall EBITDA margin from 13% to 15% plus this year.
- Medium-term ambition of 18–20%: Over a three-to-four-year journey, the intent is to take average EBITDA margins to between 18–20%, driven by product mix improvement and backward integration.
- Product selection philosophy: Focus is on adding products that have the capacity to deliver 25% plus EBITDA margin, which will pull up the overall company EBITDA margin.
- Backward integration is sequenced, not rushed: Management will backward integrate only after achieving commercial scale and asset utilization; backward integrating at 20–30% utilization does not make commercial viability. Once scale is achieved, parallel activities for export qualification and backward integration begin, driving margin expansion on both sales realization and cost of manufacturing.
- Backward integration timeline: Over the next two to three years to 2025, in key non-Ibuprofen portfolio products, wherever possible, backward integration will have been achieved; some intermediates are at the development stage, some at the validation stage.
- Gross margin improvement expected in H2 FY23: As the non-Ibuprofen contribution grows faster, gross margins are expected to improve from the second half of FY23 onwards.
- The prior peak is not the benchmark: Management explicitly states it will not achieve the ₹445 crores profitability level of the prior year in the near term and urges investors to look at the growth journey and sustainable 18–20% EBITDA levels rather than quarter-by-quarter volatility.
Chaturvedi: “I would much rather promise my investors 18, 20% EBITDA level, then show a yin-yang between 30, 35% back to 10% and then back to 30%, because that story is not sustainable.”
Portfolio Reshaping and Capital Allocation
- Ibuprofen share to shrink: Over the next three years, Ibuprofen will certainly become less than 50% of the total pharma business.
- Export mix ambition: Intent to take export contribution from 25–30% to 35%, with focus on growing export markets for both chemicals and pharma.
- Chemicals de-risking: The chemicals business will be de-risked by adding more products beyond the current single-product portfolio; new products will be at higher profitability levels.
- FY23 CAPEX of ~₹250 crore: Investment going into a combination of both chemicals and pharma, expected to give growth to both business segments.
- Regulatory filings progressing: One DMF filed with USFDA in Q4, four new DMFs filed in FY22, three CEP applications filed with EDQM, additional approvals from Korean FDA for two products, and six products approved by Russian regulatory authorities.
- Leadership investment: Significant investment made this year in leadership, training, and development; critical talent hired in the industry.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Ibuprofen volume recovery | Volume uptick to begin | From Q2 FY23 onwards |
| Ibuprofen pricing recovery | Prices to increase from current floor, driven by input cost pressure | H2 FY23, once overstocking resolves |
| Chemical business EBITDA | Return to positive single digits | Q1 FY23 |
| Chemical business EBITDA | Return to 6–8% range | FY23 (full year) |
| Overall company EBITDA margin | 15% plus | FY23 |
| Overall company EBITDA margin | 18–20% average | 3–4 year journey |
| Non-Ibuprofen API EBITDA margin | Double digits | FY23 |
| Non-Ibuprofen asset utilization | Improve to 75–80% | Next 12–18 months |
| Paracetamol capacity | Double to 3,600 tons/year | End of CY22 |
| New chemical products commercial activity | Revenue contribution to begin | FY24 |
| Chemicals division growth rate | 10–20% sustained annual growth | Ongoing target |
| Ibuprofen share of pharma | Less than 50% | Within 3 years |
| Backward integration in key non-IBU products | Achieved wherever possible | By 2025 |
| Export contribution | Increase to 35% | No fixed date |
| Metformin regulated market approvals | Entry into regulated export markets | A few more quarters |
| FY23 CAPEX | ~₹250 crore | FY23 |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Total revenue | ₹573 cr, up 3% QoQ from ₹555 cr in Q3 FY22 |
| FY22 revenue growth | 11% YoY |
| EBITDA | ₹50 cr |
| FY22 EBITDA margin | 13% |
| FY22 profit after tax | ₹166 cr, down from ₹445 cr in FY21 |
| Pharma segment EBIT margin | 37.27% (per an analyst's math) |
| Chemicals business EBITDA guidance | 6% to 8% annual average |
| Non-Ibuprofen pharma contribution to quarterly revenue | 20% |
| Non-Ibuprofen pharma contribution to pharma segment revenue | 35% |
| Ibuprofen asset utilization | ~70% |
| Ibuprofen volume decline FY22 vs FY21 | ~1,000 tons |
| Ibuprofen FY22 volumes | 8,000–8,300 tons (per an analyst's math) |
| Ibuprofen FY22 average pricing | $11 to $11.5 per kg |
| Ibuprofen installed capacity | 12,000 tonnes, vs world capacity of 35,000–36,000 tons |
| Paracetamol capacity | 1,800 tons per year, expanding to 3,600 tons by end of FY23 |
| Exports contribution to revenue | 25–30%, with intent to reach 35% |
| FY23 planned CAPEX | ₹250 cr, up from historical average of ₹150 cr |
| FY23 EBITDA margin target | 15% plus, with 3–4 year target of 18–20% |
| USFDA DMFs filed in Q4 | 1 |
| USFDA DMFs filed in FY22 | 4 |
| CEP applications filed with EDQM in FY22 | 3 |
| Patent applications filed in FY22 | 3 |